A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs SL 801 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 05 Jun 2018 Interim results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results published in the Media Release
    • 26 Apr 2018 According to a Stemline Therapeutics media release, interim results from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Jun 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top